A multicenter clinical trial in Nigeria with a low-dose oral contraceptive, Marvelon.
The monophasic combination preparation, Marvelon, is a modern, technically improved oral contraceptive. It was tested for contraceptive reliability, cycle control and acceptability in 4 clinical centers in Nigeria for a period of one year. A total of 408 women was included in these studies, and 3102 cycles were monitored. The results showed a high contraceptive reliability and an excellent cycle-control. It was well tolerated. There were very few side-effects and the symptoms during medication were minor and hardly needed any treatment. At 12 months, 43.1% of the acceptors were still in the trial. Seventy-nine women (19.4%) discontinued before the end of the study for any reason. Drop-out reasons of these women were mainly non-medical. For the remainder of drop-outs no reason was given. This study suggests that this new oral contraceptive adequately satisfies the contraceptive needs of modern women.
van Dierendonck
B
B
Organon International, Oss, The Netherlands.
Ekwempu
C C
CC
Ladipo
O A
OA
Ulasi
J N
JN
Giwa-Osagie
O F
OF
D000293:Adolescent; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D003276:Contraceptives, Oral / Q000009:adverse effects / Q000494:pharmacology / Q000592:standards*; D017135:Desogestrel / Q000009:adverse effects / Q000494:pharmacology / Q000592:standards*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D009549:Nigeria
D003276:Contraceptives, Oral; D017135:Desogestrel